MedWatch

American acquisition leads to European opportunities

A Danish medtech company’s record-breaking acquisition of King Systems in February is going according to plan so far. The next crucial step will be to integrate the company’s products on the European market, the CEO explains.

Lars Marcher, CEO in Ambu | Foto: Ambu/ PR

Over the last four months all Ambu’s attention has been focused on the integration of the American anesthesia company King Systems, which Ambu acquired for about USD 125m plus possible milestone payments and two so-called earn-out agreements. The last few months have been spent on three things in particular.

“One was securing our combined sales organisation. It has now been integrated into the organisation. Meanwhile, we have ensured that our IT systems are up and running, which usually takes years. Thirdly, our U.S. production is now a fully integrated part of our four other factories around the world. So far we haven’t focused on Europe at all. We have purposely said that anything pertaining to integration will take place in the U.S.,” CEO Lars Marcher tells Medwatch in an interview.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Eli Lilly får forlomme til fedmehåb hos FDA

Med en fast track status får medicinalselskabet Eli Lilly sænket behandlingstiden for sin registreringsansøgning hos FDA af lægemiddelhåbet Tirzepatid til omtrent seks måneder fra de normale ca. 10 måneder.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier